brukinsa capsule
beigene switzerland gmbh - zanubrutinib - capsule - 80mg - zanubrutinib 80mg - antineoplastic agents
perjeta concentrate for solution for infusion 420mg14ml
roche singapore pte. ltd. - pertuzumab - infusion, solution concentrate - 30 mg/ml - pertuzumab 30 mg/ml
cellcept for i.v. infusion 500 mgvial
roche singapore pte. ltd. - mycophenolate mofetil - injection, powder, for solution - 500 mg/vial - mycophenolate mofetil 500 mg/vial
gintuit- allogeneic cultured keratinocytes and fibroblasts in bovine collagen cellular sheet
organogenesis, inc - foreskin fibroblast (neonatal) (unii: t34c307w5n) (foreskin fibroblast (neonatal) - unii:t34c307w5n), bovine type i collagen (unii: fhj3atl51c) (bovine type i collagen - unii:fhj3atl51c), foreskin keratinocyte (neonatal) (unii: zjo8cp3q2a) (foreskin keratinocyte (neonatal) - unii:zjo8cp3q2a) - foreskin fibroblast (neonatal) - gintuit (allogeneic cultured keratinocytes and fibroblasts in bovine collagen) is an allogeneic cellularized scaffold product indicated for topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults. gintuit is not intended to provide root coverage. - do not use in the presence of oral infection. - do not use in patients with known allergies to bovine collagen. pregnancy category c. animal reproduction studies have not been conducted with gintuit. it is also unknown whether gintuit can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. gintuit should be used in a pregnant woman only if clearly needed. the safety and efficacy of gintuit in infants and children have not been established. clinical studies of gintuit did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects.
perjeta
roche diagnostics gmbh - pertuzumab - concentrate for solution for infusion - 30mg/ml
gazyva 1000mg/40ml concentrate for solution for infusion
f. hoffmann-la roche ltd. 4303 kaiseraugst- batch releaser - obinutuzumab - concentrate for solution for infusion - 1000mg/40ml
perjeta concentrate for solution for infusion
roche diagnostics gmbh - pertuzumab - concentrate for solution for infusion - 30mg/ml
gazyva concentrate for solution for infusion
f. hoffmann-la roche ltd. 4303 kaiseraugs- secondary packager - obinutuzumab - concentrate for solution for infusion - 1000mg/40ml
xolair 75mg0.5ml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - omalizumab -
xolair 150mgml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - omalizumab -